Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
The identification of immunologic biomarkers associated with clinical response after immune intervention for cancer is an area of intensive investigation. The field would benefit from a more systemic and directed approach for biomarker identification and evaluation. Lessons can be learned from other fields, such as cancer diagnostics, as to how to develop response-associated biomarkers. Studies in both human in vitro models as well as murine models of cancer can significantly inform and streamline the choice of candidates. Adoptive T-cell therapy is an interesting model for exploring potential immunologic surrogates that may predict clinical response. Most likely the clinical effectiveness of immune-based treatments will be predicted by panels of markers rather than single assays of a specific immune effector cell.
Dang
Yushe
Y
Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, WA 98109, USA. ydang@u.washington.edu
Disis
Mary L
ML
D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D015415:Biomarkers / Q000032:analysis*; D017252:CD3 Complex / Q000032:analysis; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive / Q000379:methods; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D009374:Neoplasms, Experimental / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D015703:Antigens, CD; D015415:Biomarkers; D017252:CD3 Complex